A Phase IIa, Randomized, Open-label, Proof-of-Concept Study to Evaluate Safety, Tolerability and Efficacy of Ir-CPI in Patients With Spontaneous Intracerebral Haemorrhage

The purpose of the study is to provide a first assessment of safety, tolerability and efficacy of Ir-CPI, administered on top of standard-of-care, on secondary brain injury in patients with spontaneous intracerebral haemorrhage.

开始日期2023-11-17

申办/合作机构

Bioxodes SA

NCT04653766 / Completed临床1期

A Phase I, Double Blind, Placebo Controlled, Single Ascending Dose Study of Intravenously Administered Ir-CPI to Evaluate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability in Healthy Male Volunteers

The purpose of this First-in-Human study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of Ir-CPI, a novel dual inhibitor of FXIIa and FXIa, following IV administration of single ascending doses in healthy male volunteers.

开始日期2019-09-12

申办/合作机构

Bioxodes SA

100 项与 Ir CPI 相关的临床结果

登录后查看更多信息

100 项与 Ir CPI 相关的转化医学

登录后查看更多信息

100 项与 Ir CPI 相关的专利（医药）

登录后查看更多信息

569

项与 Ir CPI 相关的文献（医药）

2024-12-01·ULTRASONICS SONOCHEMISTRY

Enhancement of extraction efficiency and functional properties of chickpea protein isolate using pulsed electric field combined with ultrasound treatment

Article

作者: Zeng, Xin-An ; Huang, Yan-Yan ; Lin, Song-Yi ; Faisal Manzoor, Muhammad ; Li, Jian ; Lai, Xin-Jue ; Nie, Jing ; Wang, Rui ; Guo, Pei-Feng ; Chen, Jian-Quan

Chickpea protein isolate (CPI) is a promising dietary protein with the advantages of low allergenicity, easy digestion and balanced composition of essential amino acids. However, due to the thick skin of chickpeas, the extraction of CPI is challenging, resulting in lower efficiency of the alkaline extraction-isoelectric precipitation (AE-IEP) method. Therefore, the present study investigated the effect of pulsed electric field combined with ultrasound (PEF-US) treatment on the extraction efficiency of CPI and the functional properties was characterized. Parameter optimization was carried out using response surface methodology (RSM), with the following optimized conditions: pulse duration of 87 s, electric field intensity of 0.9 kV/cm, ultrasonic time of 15 min, and ultrasonic power of 325 W. Under the optimized conditions, the yield of CPI after combined (PEF-US) treatment was 13.52 ± 0.13 %, which was a 47.28 % improvement over the AE-IEP method. This yield was better than that obtained with either individual PEF or US treatment. Additionally, the functional properties (solubility, emulsification, and foaming) of CPI were significantly enhanced compared to AE-IEP. However, the stability of emulsification and foaming did not show significant differences among the four methods. The PEF-US method efficiently extracts CPI with excellent functional properties, enabling the production of proteins as desired functional additives in the food industry.

2024-10-22·ACS Omega

Little-Cost Potentiometric and Spectrophotometric Procedures for Cephalothin Assessment in Pure and Biological Fluids

Article

作者: A. Farghaly, Othman

Low-cost potentiometric and spectrophotometric procedures for cephalothin (CPI) determination in pure and biological fluids were investigated. The potentiometric technique is created through titration of CPI with an aqueous medium of 0.1 M NaOH at an ionic strength of μ = 0.3 M sodium chloride and room temperature by a combined glass pH electrode. Using the standard addition method, we found that the detection and quantitative limits were 0.042 mg/mL, with the standard deviation SD = 0.011, correlation coefficient R = 0.9880 (n = 5), and linear concentration ranges from 0.042 to 0.82 mg/mL. This technique was utilized to assess CPI in pure solutions, urine, and serum with suitable results. No interference was exposed in the presence of public components of the samples under study. Recovery of CPI for pure and biological fluids is in the range of 98.2-101%. Also, the spectrophotometric method has been performed through the formation of the Prussian Blue (PB) complex. The reaction between the acidic hydrolysis product of CPI (T = 60 °C) and the mixture of Fe³⁺ with hexacyanoferrate (III) ions (HCF(III)) was detected for the spectrophotometric determination of the drug. The maximum absorbance of the formed complex was measured at λ = 283 nm with 2.0 × 10³ L mol^-1 cm^-1 molar absorptivity. Reaction states have been advanced to acquire the PB complex of great sensitivity and longer stability. In optimal states, the absorbent of the PB compound was attained to grow linearly with the increase in the concentration of CPI, which agrees with the correlation coefficient values. The detection and quantitative limits were 0.000036 and 0.0012 mg/mL, respectively, with the standard deviation, SD = 0.0005, correlation coefficient, R = 0.9955 (n = 5), and the linearity range of the calibration plot 0.0005-0.02 mg/mL CPI. The planned technique was positively utilized for the detection of CPI in both urine and serum models. The results fit well with the data found from the potentiometric method.

2024-10-10·JOURNAL OF CLINICAL ONCOLOGY

TROPHY-U-01 Cohort 2: A Phase II Study of Sacituzumab Govitecan in Cisplatin-Ineligible Patients With Metastatic Urothelial Cancer Progressing After Previous Checkpoint Inhibitor Therapy

Article

作者: Sternberg, Cora N. ; Nordquist, Luke ; Palmbos, Phillip ; Loriot, Yohann ; Petrylak, Daniel P. ; Park, Chandler ; Kalebasty, Arash Rezazadeh ; George, Saby ; Balar, Arjun ; Jain, Rohit K. ; Vance, Morganna ; Tagawa, Scott T. ; Davis, Nancy ; Agarwal, Neeraj ; Tonelli, Julia ; Ramamurthy, Chethan ; Bupathi, Manojkumar ; Zhou, Huafeng ; Grivas, Petros

PURPOSE:

Sacituzumab govitecan (SG) is a Trop-2–directed antibody-drug conjugate with an SN-38 payload, approved for patients with locally advanced (LA) or metastatic urothelial cancer (mUC) who progressed after platinum (PT)-based chemotherapy and a checkpoint inhibitor (CPI). Here, we report results from Cohort 2 of TROPHY-U-01 trial, evaluating the efficacy and safety of SG in patients with mUC.

METHODS:

TROPHY-U-01 (ClinicalTrials.gov identifier: NCT03547973 ) is a multicohort, open-label phase II study. Cohort 2 includes patients with LA or mUC who have had progression or recurrence after a CPI and were cisplatin-ineligible at study initiation. Patients received SG 10 mg/kg on days 1 and 8 of 21-day cycles. The primary end point was objective response rate (ORR) per central review; secondary end points were clinical benefit rate (CBR), duration of response (DOR), and progression-free survival (PFS) per central review and safety.

RESULTS:

Cohort 2 included 38 patients (61% male; median age 72.5 years; 66% visceral metastases [29% liver]; 50% received previous PT-based chemotherapy as previous [neo]adjuvant therapy]). At a median follow-up of 9.3 months, ORR was 32% (95% CI, 17.5 to 48.7), CBR 42% (95% CI, 26.3 to 59.2), median DOR 5.6 months (95% CI, 2.8 to 13.3), median PFS 5.6 months (95% CI, 4.1 to 8.3), and median overall survival 13.5 months (95% CI, 7.6 to 15.6). Grade ≥3 treatment-emergent adverse events occurred in 87% of patients, most commonly neutropenia (34%), anemia (24%), leukopenia (19%), fatigue (18%), and diarrhea (16%).

CONCLUSION:

SG monotherapy demonstrated a relatively high ORR with rapid responses; this was feasible with a manageable toxicity profile in cisplatin-ineligible patients who had progression after CPI therapy. Limitations include a moderate sample size and lack of random assignment. These results warrant further evaluation of SG alone and in combinations in patients with LA/mUC.

项与 Ir CPI 相关的新闻（医药）

2024-09-14

·生物探索

Nature Genetics | 揭示免疫治疗新篇章：五大潜在因素助力免疫检查点抑制剂（CPI）疗效精准预测

引言免疫检查点抑制剂（CPI）的应用为癌症治疗带来了革命性的突破，尤其在一些难治性肿瘤如黑色素瘤和非小细胞肺癌中展现出显著疗效。然而，尽管CPI在临床上取得了成功，但其疗效并非普遍适用于所有患者。只有部分患者对CPI治疗产生积极的响应，而另一些患者则表现为无效或有限的疗效。导致这一差异的关键在于肿瘤本身及其微环境的多样性。为了进一步揭示患者对CPI响应的潜在机制，研究者们着手探索影响CPI疗效的生物标志物。目前已有多项研究提出了潜在的CPI响应预测因子，例如肿瘤突变负荷（TMB）、程序性死亡配体-1（PD-L1）表达水平、以及肿瘤微环境中的免疫细胞浸润程度。然而，这些标志物之间可能存在相互重叠和关联性，尚不清楚有多少独立的生物标志物确实在预测CPI疗效中发挥作用。 9月12日Nature Genetics的研究报道“Five latent factors underlie response to immunotherapy”，通过无偏分析，整合基因组、转录组和临床数据，以识别与CPI响应和患者生存期密切相关的潜在因素。该研究纳入了479名患有转移性肿瘤的患者，采用全基因组测序（WGS）和全转录组测序（RNA-seq）技术，系统分析了患者的基因突变、基因表达、以及与免疫反应相关的特征。研究结果发现，CPI疗效和患者生存期的关键驱动因素可以归纳为五个独立的潜在因素：肿瘤突变负荷（TMB, Tumor Mutation Burden），T细胞有效浸润（T Cell Effective Infiltration），转化生长因子-β（TGF-β, Transforming Growth Factor-Beta）活性，既往治疗（Prior Treatment），肿瘤增殖潜力（Proliferative Potential）。通过对这五个潜在因素的深入分析，研究人员能够对不同类型的肿瘤进行系统分类，从而更好地预测患者对CPI治疗的响应情况。进一步的验证研究表明，这五个潜在因素不仅在原始研究队列中适用，还在六个独立的患者队列中得到了广泛验证，涵盖了多种癌症类型。这五个潜在因素为当前和未来关于CPI响应和生存期的生物标志物研究提供了框架。基于这些因素，未来可以开发更加精准的个体化治疗方案，提高CPI治疗的成功率，并减少治疗的副作用和经济负担。这一研究为癌症免疫治疗的进一步优化奠定了基础，并为未来在临床中应用多变量模型预测CPI疗效提供了方向。免疫检查点抑制剂（CPI）是近年来癌症治疗领域的重要突破，通过抑制肿瘤细胞对免疫系统的逃逸机制，CPI在一些肿瘤类型中取得了显著疗效。然而，并非所有患者都能从中获益，疗效的差异性引发了对潜在生物标志物的探索。该研究旨在通过基因组、转录组和临床数据的整合分析，识别与CPI响应密切相关的生物标志物，并验证其在多个独立队列中的普适性。研究使用了来自HMF-CPI数据库的479名转移性肿瘤患者的全基因组测序（WGS）和全转录组测序（RNA-seq）数据。研究提取了27,923个特征，包括单核苷酸变异、拷贝数变异、结构变异、肿瘤突变负荷（TMB）、免疫浸润细胞类型、TGF-β活性、既往治疗情况和肿瘤增殖潜力等。研究通过无监督聚类和回归分析，将这些特征归为五个潜在因素，并通过多个独立队列验证这些因素的广泛适用性。从HMF-CPI队列中提取特征的过程，重点展示了研究中如何从479名接受免疫检查点抑制剂（CPI）治疗的转移性肿瘤患者的样本中提取和分析基因组、转录组以及临床数据（Credit: Nature Genetics）研究中的患者样本包括5,000多个转移性肿瘤患者，其中479名患者接受了CPI治疗。研究生成了超过27,000个特征用于分析，并通过多变量模型验证了这些特征与CPI响应和生存期的关联性。研究结果在六个独立验证队列中得到了广泛验证，这些队列包括不同类型的肿瘤患者，进一步证明了研究发现的普适性。通过无偏分析，研究者揭示了与CPI响应密切相关的五个潜在因素，这些因素能够预测患者的治疗效果，并为个性化免疫治疗提供了依据。免疫检查点抑制剂（CPI）治疗响应密切相关的三个潜在因素，并通过分析这些因素对患者生存期和治疗效果的影响，揭示了它们在不同肿瘤类型中的应用（Credit: Nature Genetics）与患者生存期密切相关的两个潜在因素，并进一步分析了这些因素如何影响接受免疫检查点抑制剂（CPI）治疗的患者的生存结果（Credit: Nature Genetics）肿瘤突变负荷（TMB, Tumor Mutation Burden） TMB是指肿瘤中的突变数量，研究表明TMB越高，患者对CPI的响应越好。TMB高的患者通常生存期更长，表明高TMB能够激发更强的免疫反应。这一结果通过多个独立验证队列的分析得到了支持。 T细胞有效浸润（T Cell Effective Infiltration） T细胞是肿瘤免疫反应的关键，研究发现T细胞浸润多的患者对CPI响应更好，生存期更长。在该研究中，T细胞浸润与多个基因集的表达呈显著正相关，验证了T细胞在肿瘤免疫监控中的重要性。转化生长因子-β（TGF-β, Transforming Growth Factor-Beta）活性TGF-β在肿瘤微环境中的活性是CPI疗效的负面因素。研究表明，TGF-β活性高的患者生存期较短，表明高TGF-β活性抑制了免疫系统的有效反应。降低TGF-β活性可能提高CPI疗效。既往治疗历史（Prior Treatment History）患者的既往治疗对CPI响应有显著影响。研究发现，接受过更多化疗或放疗的患者对CPI响应较差，可能是由于这些治疗削弱了患者的免疫系统，或者导致肿瘤细胞更具抗性。肿瘤增殖潜力（Proliferative Potential）肿瘤增殖能力较强的患者通常预后较差，表现为较短的生存期。研究表明，肿瘤增殖潜力与CPI响应呈负相关，增殖能力越强的肿瘤对CPI疗效越低。对独立队列中的潜在因素进行验证的结果，旨在评估这些潜在因素在不同患者群体和肿瘤类型中预测免疫检查点抑制剂（CPI）治疗效果和生存期的广泛适用性（Credit: Nature Genetics）研究结果不仅验证了TMB、T细胞浸润和TGF-β活性等传统生物标志物的作用，还发现了肿瘤增殖潜力和既往治疗对CPI响应的独特影响。通过多变量模型预测患者对免疫检查点抑制剂（CPI）治疗的响应和生存期的结果（Credit: Nature Genetics）这项研究为癌症免疫治疗中的生物标志物提供了新的见解，并首次系统地揭示了影响CPI疗效的五个潜在因素。这些因素为未来开发个性化的癌症治疗方案奠定了基础，帮助医生根据患者的具体生物特征制定更加精准的治疗计划，提高治疗的成功率并减少副作用。总之，该研究通过对大规模患者队列的全面分析，揭示了肿瘤微环境、基因组和既往治疗对CPI疗效的复杂影响，为未来的癌症免疫治疗提供了新的思路。参考文献 Usset J, Rosendahl Huber A, Andrianova MA, Batlle E, Carles J, Cuppen E, Elez E, Felip E, Gómez-Rey M, Lo Giacco D, Martinez-Jimenez F, Muñoz-Couselo E, Siu LL, Tabernero J, Vivancos A, Muiños F, Gonzalez-Perez A, Lopez-Bigas N. Five latent factors underlie response to immunotherapy. Nat Genet. 2024 Sep 12. doi: 10.1038/s41588-024-01899-0. Epub ahead of print. PMID: 39266764. https://www-nature-com.libproxy1.nus.edu.sg/articles/s41588-024-01899-0 责编|探索君排版|探索君转载请注明来源于【生物探索】 End 往期精选围观一文读透细胞死亡(Cell Death) | 24年Cell重磅综述（长文收藏版）热文 Cell | 是什么决定了细胞的大小？热文 Nature | 2024年值得关注的七项技术热文 Nature | 自身免疫性疾病能被治愈吗？科学家们终于看到了希望热文 CRISPR技术进化史 | 24年Cell 综述

免疫疗法

2024-08-21

·GlobeNewswire-Health Care

Bioxodes reports positive DMC meeting for BIOX-101 Phase 2a trial in intracerebral hemorrhagic stroke

Planned Data Monitoring Committee (DMC) meeting recommended continuation of the study after reviewing data from the first 8 patients Interim data from 16 patients scheduled around the end of 2024 Gosselies (Belgium), August 21, 2024 – Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies to prevent and treat thrombotic and inflammatory diseases, announces today that the DMC reviewed the data from the first 8 patients in a planned review of the ongoing BIRCH Phase 2a trial of BIOX-101 to prevent secondary damage after intracerebral hemorrhagic stroke (ICH). The randomized, open-label, controlled Phase 2a clinical study is designed to enroll 32 patients. In the study, intravenous BIOX-101 treatment is initiated within the first hours from onset. To date, no serious adverse events related to BIOX-101 have been reported and none of the patients have died. Although only 13% of strokes are classified as ICH, it is a devastating condition and accounts for 40% of all stroke-related deaths, leaving many survivors with permanent or long-term disability. There is currently no approved treatment for these patients. “We are highly encouraged by the DMC’s decision and the fact that there have been no safety issues” said Marc Dechamps, Chief Executive Officer at Bioxodes. BIOX-101 is a first-in-class drug candidate derived from a protein found in tick saliva1. “It is well known that the saliva of the tick has the ability to modulate the immune response and the defence mechanisms of the host” pointed out Edmond Godfroid, PhD, co-founder and Chief Scientific Officer of Bioxodes. “Because BIOX-101 has shown strong anti-inflammatory and antithrombotic properties but does not increase the risk of bleeding, we are testing its ability to prevent the harmful secondary brain injuries that occur in most ICH patients. While we are eager to test BIOX-101 in ischemic stroke and other diseases, ICH is considered an orphan disease in U.S. and Europe, offering a relatively rapid and more cost-effective path to market” adds Marc Dechamps. After treating the first 8 patients in the open-label trial, the company is conducting a preliminary analysis of pharmacokinetic and pharmacodynamic data to evaluate the dose-response and efficacy of BIOX-101. Bioxodes may make the data available to select potential partners or investors under confidentiality. The recommendation by the DMC, an independent group of experts overseeing the study, allows the company to enroll the next 24 patients. The company expects an interim data read-out based on the first 16 patients around the end of the year. The study, conducted in 10 stroke units in Belgium and led by Prof Robin Lemmens, a world-leading stroke authority and head of clinic at the University Hospital Leuven, aims to enroll up to 32 ICH patients aged 18 or older, with 24 receiving BIOX-101, and 8 standard-of-care treatment. Standard-of-care consists largely of monitoring and stabilizing the patient without the use of anticoagulant medication, which increases the risk of secondary damage, a major threat that often causes death or long-term disability.The study will evaluate the safety and tolerability of BIOX-101 in patients with spontaneous ICH, while also generating preliminary data on efficacy. All patients will be monitored for at least one year to evaluate the impact of the treatment on long-term functional outcomes. BIOX-101 works by preventing blood clot formation without increasing the risk of further bleeding, the way anticoagulants do. Moreover, by inhibiting the activation of neutrophils, a type of white blood cell that often act as the first responders of the inflammatory system, it also prevents the acute neuroinflammatory events associated with ICH. BIOX-101 is also in early development as a platform for a series of other indications, including ischemic stroke and other thrombo-inflammatory diseases. About Bioxodes Bioxodes (www.bioxodes.com) is a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases. Since its founding in 2013, Bioxodes has developed its lead asset BIOX-101, a first-in-class drug candidate aimed at patients with thrombo-inflammatory disease. BIOX-101’s unique mechanism of action is the foundation of an innovative pipeline of drug candidates for the prevention of (thrombo)inflammatory diseases. The company, which is based in the biopark of Gosselies near Brussels in Belgium, has so far secured €34 million in funding from Belgian investment funds and business angels, including €12 million in non-dilutive funding from the Wallonia region. Worldwide, Bioxodes holds both granted and pending patents associated with BIOX-101. 1 Ixodes ricinus For more information please contact: BioxodesBioPark Charleroi-Bruxelles SudRue Santos-Dumont, 16041 Gosselies, Belgium+32 496 590354 Belgian Media ContactAlexandra Schiettekatte investment@bioxodes.comMobile: +32 476 65 04 38 Investor RelationsGiovanni Ca’ ZorziCohesion Bureaugiovanni.cazorzi@cohesionbureau.comMobile: +33 7 84 67 07 27 International MediaSophie BaumontCohesion Bureausophie.baumont@cohesionbureau.comMobile: +33 6 27 74 74 49 Attachment 20240821 Bioxodes PKPD data_FINAL_EN

临床2期

2024-06-27

·BioSpace

Bioxodes meets first Phase 2a patient enrollment milestone with BIOX-101 in intracerebral hemorrhagic stroke

First-in-class drug candidate evaluated in first eight patients Gosselies (Belgium), June 27, 2024 – Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, announces today that it has enrolled the first eight of 32 patients in a Phase 2a clinical study of its lead asset BIOX-101 (Ir-CPI). The study is evaluating BIOX-101 in intracerebral hemorrhagic stroke (ICH), a devastating condition for which there is currently no available treatment. Reaching this first milestone allows Bioxodes to conduct an initial analysis of pharmacokinetic and pharmacodynamic data to evaluate the dose-response and preliminary clinical proof-of concept of the therapeutic candidate, as well as safety in this patient population. “For the first time, we are able to assess the preliminary results of BIOX-101 in ICH patients, who up until now have had very few treatment options. Analysis of these first 8 patients will yield preliminary proof-of-concept data for BIOX-101, a first-in-class drug candidate derived from a protein found in the saliva of the tick 1, designed to prevent the harmful secondary brain injuries that occur after a hemorrhagic stroke,” said Marc Dechamps, Chief Executive Officer at Bioxodes. The study, conducted in 10 stroke units in Belgium and led by Prof Robin Lemmens, a world-leading stroke authority and head of the clinic at the University Hospital Leuven, aims to enroll 32 patients aged 18 and above, with 24 receiving BIOX-101, and 8 standard-of-care treatment. The trial is a randomized, open-label proof-of-concept study, and will evaluate the safety and tolerability of BIOX-101 in patients with spontaneous ICH, while also generating preliminary data on secondary efficacy objectives. All patients will be monitored for at least one year to evaluate the impact of the treatment on long-term functional outcomes. Interim results for the first 16 patients are expected by the fourth quarter of 2024. BIOX-101 prevents blood clot formation without increasing the risk of further bleeding. Moreover, by inhibiting the activation of neutrophils, a type of white blood cell that often act as the first responders of the inflammatory system, it also prevents the acute neuroinflammatory events associated with ICH. BIOX-101 is also in early development as a platform for a series of other indications, including ischemic stroke and other thrombo-inflammatory diseases. KEY FACTS ABOUT STROKE: * 15 million people worldwide suffer from a stroke each year, * Of those, 5 million die, another 5 million are left severely disabled * Stroke is the leading cause of disability among neurological conditions worldwide, according to the Global Burden of Disease Study 2021 (Lancet Neurology May 2024). * Two types: ischemic stroke (caused by a blood clot) and hemorrhagic stroke (ruptured vessel) * Hemorrhagic stroke makes up 13% of all cases, but causes 40% of deaths * Intracerebral hemorrhagic stroke (ICH) is by far the most common type of hemorrhagic stroke * For hemorrhagic stroke, there is little other to do than surgery, with poor outcomes * Bioxodes has applied for an orphan disease designation for BIOX-101 in the US and EU. Being awarded the designation could accelerate the regulatory approval process. 1 Ixodes ricinus About Bioxodes Bioxodes is a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases. Since its founding in 2013, Bioxodes has developed its lead asset BIOX-101, a first-in-class drug candidate aimed at patients with thrombo-inflammatory disease. BIOX-101’s unique mechanism of action is the foundation of an innovative pipeline of drug candidates for the prevention of (thrombo)inflammatory diseases. The company, which is based in the biopark of Gosselies near Brussels in Belgium, has so far secured €34 million in funding from Belgian investment funds and business angels, including €12 million in non-dilutive funding from the Wallonia region. Worldwide, Bioxodes holds both granted and pending patents associated with BIOX-101. For more information please contact: HEAD OFFICES BioPark Charleroi-Bruxelles Sud Rue Santos-Dumont, 1 6041 Gosselies, Belgium +32 496 590354 investment@bioxodes.com MEDIA RELATIONS Alexandra Schiettekatte alexandra.alicato@outlook.com +32 476 65 04 38 COHESION BUREAU EU MEDIA RELATIONS Sophie Baumont sophie.baumont@cohesionbureau.com INVESTOR RELATIONS Giovanni Ca’ Zorzi giovanni.cazorzi@cohesionbureau.com Attachment 20240627 Bioxodes PR first 8 patients (final) EN

临床2期孤儿药

100 项与 Ir CPI 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
脑出血	临床2期	比利时	Bioxodes SA	2023-11-17
出血性卒中	临床2期	-	Bioxodes SA	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04653766 (CTgov)	临床1期	-	32	Ir-CPI - Dose 1 (Ir-CPI - Dose 1)	範醖膚遞願積鑰糧願鬱(遞鑰範範願膚淵醖簾製) = 鑰選蓋衊夢獵鏇顧衊衊鬱襯蓋網鹹顧夢鹹襯壓 (鏇獵簾願壓餘醖鏇鑰衊, 蓋鹹繭繭鹽構淵遞糧襯 ~ 願蓋鏇製網鏇夢衊衊窪) 更多	-	2021-05-27
				Ir-CPI - Dose 2 (Ir-CPI - Dose 2)	範醖膚遞願積鑰糧願鬱(遞鑰範範願膚淵醖簾製) = 鹽餘鑰憲艱齋顧繭鬱觸鬱襯蓋網鹹顧夢鹹襯壓 (鏇獵簾願壓餘醖鏇鑰衊, 構選艱夢築積夢襯淵鹽 ~ 淵廠蓋蓋衊製構糧淵餘) 更多